CONTEXT AND OBJECTIVE: Studies using radionuclides are the most appropriate method for estimating renal function. Dimercaptosuccinic acid chelate labeled with technetium-99m ( 99m Tc-DMSA) is the radiopharmaceutical of choice for high-resolution imaging of the renal cortex and estimation of the functional renal mass. The aim of this study was to evaluate a simplifi ed method for determining the absolute renal uptake (ARU) of 99m Tc-DMSA prior to nephrectomy, using the radioactivity counts of nephrectomy specimens as the gold standard.
CONTEXT AND OBJECTIVE: Studies using radionuclides are the most appropriate method for estimating renal function. Dimercaptosuccinic acid chelate labeled with technetium-99m ( 99m Tc-DMSA) is the radiopharmaceutical of choice for high-resolution imaging of the renal cortex and estimation of the functional renal mass. The aim of this study was to evaluate a simplifi ed method for determining the absolute renal uptake (ARU) of Tc-DMSA prior to nephrectomy, using the radioactivity counts of nephrectomy specimens as the gold standard.
DESIGN AND SETTING:
Prospective study at the Division of Nuclear Medicine, Department of Radiology, Universidade Estadual de Campinas.
METHODS:
Seventeen patients (12 females; range 22-82 years old; mean age 50.8 years old) underwent nephrectomy for various reasons. Renal scintigraphy was performed three to four hours after intravenous administration of a mean dose of 188.7 MBq (5.1 mCi) of 99m Tc-DMSA, which was done six to 24 hours before surgery. The in vivo renal uptake of 99m Tc-DMSA was determined using the radioactivity of the syringe before the injection (measured using a dose calibrator) and the images of the syringe and kidneys, obtained from a scintillation camera. After surgery, the reference value for renal uptake of 99m Tc-DMSA was determined by measuring the radioactivity of the nephrectomy specimen using the same dose calibrator.
INTRODUCTION
Studies using radionuclides are the most appropriate method for estimating renal function, to add functional information to anatomical studies such as ultrasound and X-ray methods. Dimercaptosuccinic acid chelate labeled with technetium-99m ( 99m Tc-DMSA) was introduced in the early 1970s 1,2 and, ever since, it has been the radiopharmaceutical of choice for high-resolution imaging of the renal cortex and estimation of the functional renal mass. 3 Several studies have demonstrated excellent correlation between 99m Tc-DMSA uptake and creatinine clearance, 4 para-aminohippuric acid (PAH) clearance 5 and renal technetium99m diethylenetriamine pentaacetic acid ( 99m Tc-DTPA) accumulation. 6, 7 Different techniques to measure the absolute uptake of Tc-DMSA by the kidneys have been described using planar scintigraphy and single photon emission computed tomography (SPECT), but the methods remain too complex for routine use. 8, 9 Moreover, none of these techniques for in vivo quantifi cation of isolated renal 99m Tc-DMSA uptake has been compared with ex vivo determination of renal uptake.
OBJECTIVE
The aim of this study was to evaluate a simplifi ed method for determining the absolute renal uptake (ARU) of 99m Tc-DMSA, using the radioactive counts from nephrectomy specimens as the reference.
METHODS

Type of study
This was a prospective study conducted in a tertiary public institution.
Patients
Seventeen patients were studied: twelve females and fi ve males, ranging from 22 to 82 years of age (mean 50.8 years). All of these patients had been selected for nephrectomy by means of open or laparoscopic surgery, because of chronic pyelonephritis (eleven patients) or neoplasia (six patients) ( Table 1 ). All patients signed a consent form that had been approved by the Institution's Ethics Committee.
The weight (in kg) and height (in cm) of all patients were measured for subsequent use in the Tonnensen equations for kidney depth estimation 10 (see image processing).
Radiopharmaceutical preparation
The radiopharmaceutical was reconstituted in accordance with the manufacturer's instructions (CIS Bio International DMSA agent, Gif-sur-Yvette, France; IPEN Molybdenum generator [Mo-99-Tc99m], São Paulo, Brazil).
The labeling effi ciency was determined by means of thin layer chromatography silica gel (TLC-SG) kits (Merck, Darmstadt, Germany). The syringes with the doses of 99m Tc-DMSA were measured in a dose calibrator (Capintec CRC-15R, Ramsey, New Jersey, United States). The doses ranged from 173.9 to 207.2 MBq (4.7 to 5.6 mCi), with a mean dose of 188.7 MBq (5.1 mCi). After intravenous injection, the residual radioactivity of the syringes was also measured. The radioactivity administered to the patients was calculated by subtracting this residual radioactivity from the syringe radioactivity before injection.
Syringe images
The syringes containing the 99m Tc-DMSA dose were imaged before intravenous adminis-tration to the patients, to determine the efficiency of the scintillation camera detector. The images were acquired for 120 seconds (matrix 256 x 256, zoom 1.8) in a single-head scintillation camera equipped with a high-resolution collimator (SP4 HR Elscint-General Electric, Haifa, Israel).
To keep the radioactivity measured in the syringes within the linear range of the detector, the syringes were placed inside a lead cylinder during acquisition. This lead cylinder was developed by the Institution's Physics Division and consisted of a cylindrical polyvinyl chloride (PVC) tube of 3.8 cm in diameter by 20.3 cm in length inside a lead sheath of 0.1 cm in thickness. The attenuation correction factor was obtained experimentally, as follows.
Determination of the lead device attenuation correction factor
Radioactivity counts were acquired ten times for each of five samples of technetium-99m with different radioactivity levels (18.5 MBq; 37 MBq; 74 MBq; 148 MBq; 222 MBq) with the syringes inside the lead cylinder, using the same scintillation camera and acquisition parameters. All acquisitions were then repeated without the lead cylinder.
After decay and background corrections, the mean count for each technetium-99m sample was determined. The data obtained with and without the lead device were plotted on two graphs and the attenuation correction factor for the cylinder was then obtained by dividing the two angular coefficients, resulting in the factor 2.8087.
Patient images
Renal scintigraphy was performed three to four hours after administering the radiopharmaceutical, and six to 24 hours prior to surgery. Posterior view images in the supine position (matrix 256 x 256; zoom 1.8) were acquired with 800,000 counts, using the same camera as used for syringe imaging ( Figure 1A ). Tracer extravasation to soft tissue during injection did not occur in any of the patients, as demonstrated by imaging each patient's injection site.
The same couch and position used to acquire the patient images were also used to acquire the syringe image, in order to standardize the attenuation factor.
Image processing
Determination of renal counts per second
Using the isocontour method (30%), regions of interest (ROIs) were drawn over the kidneys that would be removed. All ROIs were visually checked for accuracy. In four cases, the ROI was not properly drawn by the isocontour method, and a new ROI was manually drawn. The number of counts per second in the kidneys was determined.
Background corrections were performed using ROIs around the kidneys. All values were corrected for radioactive decay.
Estimation of kidney depth:
The depth of the kidneys in centimeters was estimated by the Tonnensen equations, The count per second was obtained from the syringe images, with correction for radioactive decay, and multiplication by the attenuation factor (2.8087).
Estimation of the ARU of 99m
Tc-DMSA using the images The estimation of the ARU was based on the efficiency of the detector (counts/MBq x seconds), by dividing the syringe count per second before injection by the radioactivity of the same syringe measured by the dose calibrator.
Syringe count per second before injection
Radioactivity of the syringe before injection Efficiency of the detector =
The ARU was then calculated using the images of the kidneys before nephrectomy:
Renal corrected count per second/ efficiency of the detector Radioactivity administered to the patient ARU using nephrectomy specimen images (ex vivo renal images) for evaluating the attenuation correction accuracy Immediately after surgery, posterior view images of the nephrectomy specimens were obtained using the same scintillation camera as before, with the same acquisition parameters ( Figure 1B ). These images were not subjected to soft tissue attenuation (except for the attenuation of the renal parenchyma itself ).
All ARU values were then recalculated using these images and the equation described above. These values were compared with the values obtained from the in vivo images and with the reference value.
Determination of the reference value for the ARU of 99m Tc-DMSA Each nephrectomy specimen was placed in a plastic bag and fitted in the same dose calibrator chamber that had been used for radioactivity measurement on the syringes. After correcting all measurements for radioactive decay, the reference value for the ARU was determined for each excised kidney ( Figure 1C ) as a percentage of the injected dose, by dividing the nephrectomy specimen radioactivity by the injected dose radioactivity and multiplying by 100%, as follows:
Reference value of ARU = (specimen radioactivity/injected radioactivity) x 100%.
Statistical analysis
Linear regression analysis was used to compare the ARU calculated using in vivo and ex vivo images with the ARU from the reference method. It was also applied to compare the ARU values measured with the in vivo and ex vivo images in order to evaluate the similarity of these values, which is related to the accuracy of the attenuation correction method applied to the in vivo images of kidneys.
Results
The labeling efficiency of the radiopharmaceutical ranged from 98.7% to 99.3%. The mean ARU values obtained with the in vivo and ex vivo images and with the reference method were, respectively, 5.6%, 6.4% and 6.8%. The calculated ARU values for all patients are listed in Table 2 .
The linear regression analysis comparing the ARU values obtained with the in vivo and ex vivo images and the reference method resulted in r-squared of 0.96 (in vivo image and the reference method, Figure 2 ) and 0.99 (ex vivo image and the reference method; Figure 3) .
The attenuation correction method applied to the in vivo images was found to be efficient, since the values obtained with the in vivo and ex vivo images were very similar, with r-squared of 0.95. discussion Determination of the functional capability of an individual kidney is particularly important when nephrectomy is being considered. Many studies have evaluated different methods for quantifying 99m Tc-DMSA uptake. 8, 9, 12 However, few studies have specifically addressed the use of the ARU measurement to evaluate the kidneys for nephrectomy purposes. 13, 14 When surgery is considered, very precise measurement of the absolute renal function is important, since chronic renal failure after nephrectomy is a possibility. 13 In addition, we have observed that nephrectomy provides a good opportunity to check the efficiency of the method used for absolute renal uptake estimation using 99m Tc-DMSA. Goldraich et al. 15 also determined the absolute renal uptake in 142 children with vesicoureteral reflux based on the percentage of the injected dose of 99m Tc-DMSA. Their technique was similar to that described by Raynaud 16 using 197 Hg-chlormerodrin ( 197 HgCl 2 ), which was an innovative quantitative method at that time. Goldraich et al. 15 reported a significant association between the degree of reflux nephropathy and the functional impairment measured by 99m Tc-DMSA uptake. Their technique needed a correction factor consisting of standard radioactivity for renal depth, calculated according to a decreasing exponential curve that was obtained by plotting a series of measurements of the standard against increasing thicknesses of a Plexiglas ® cover. Morris et al. 17 measured the absolute renal uptake of 99m Tc-DMSA in 160 children, based on injected counts, by subtracting the count in the syringe after injection from the count before injection. The attenuation correction used the geometric mean count between the anterior and posterior positions. They considered the thickness of the patient's intervening tissue at the center of each kidney, measured with the patients in the prone and supine positions. They determined the count in the syringe before injection by acquiring an image for only five seconds, in order to avoid pixel overflow in the computer. In the present study, we preferred to use a lead cylinder attenuator.
Groshar et al. proposed the use of a quantitative SPECT method to estimate the absolute renal function, 12 based on the technique of Iosilevsky et al. 18 The latter is a very sophisticated method that avoids the need for renal depth determination. However, it is laborious and impractical, and depends on specific site standardizations, including the need to determine the threshold value for each institution. Groshar et al. 12 did not use a gold standard test to confirm their final results.
In the present method, we performed attenuation correction by using the renal depth estimated by the Tonnensen equations. 10 which are simple for routine use and have been used by several authors. 19, 20 These equations may underestimate renal depth, as previously described by Taylor et al. 21 Nevertheless, we were able to check the efficiency of this method by comparing the ARU measurements of the in vivo and ex vivo images, which turned out to be very similar, with excellent correlation (r-squared = 0.95).
The use of the cylindrical device made of lead and PVC was essential for keeping the radioactivity dose within the linear range of the scintillation camera detector, with correction of the error due to dead time loss. A device of this nature can be easily developed in any institution.
In this study, we evaluated a simple method for determining the ARU before surgery using a reliable gold standard, which consisted of direct measurement of renal radioactivity in the nephrectomy specimen. The ARU values obtained were very similar to those of the reference method, with r-squared of 0.96. Using simple parameters, namely the radioactivity and count in the syringe and the count in the kidney, this method is easy to introduce into routine clinical practice. In particular, measurement of the radioactivity and acquisition of an image of the syringe inside the lead device is necessary only once a day. Thus, the only parameters needed for each patient are the injected dose and the count in the kidney.
It is important to emphasize that the method proposed here was only performed on entopic kidneys that were being considered for nephrectomy, mostly with severely reduced function. Further studies are necessary in order to evaluate whether this method would be feasible for ectopic organs and kidneys with normal or mildly impaired function.
The optimal time at which to determine the absolute renal uptake of 99m Tc-DMSA has been reported to be six hours after injection.
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By that time, it is postulated that the uptake will have reached a plateau. 22 However, for ideal imaging characteristics, a time interval of 2-4 hours between injection and imaging is optimal, without any significant effect on absolute 99m Tc-DMSA uptake. 23 The difference between the values obtained four hours and six hours after injection is less than 6%. 24 The fact that the in vivo images were acquired three to four hours after administering the radiopharmaceutical, while the images of the nephrectomy specimens were acquired six to 24 hours later could represent a potential error in the in vivo ARU values, compared with the specimen ARU values. Nevertheless, we found a high correlation between the in vivo and specimen ARU values (rsquared = 0.96), which suggests that there was no significant change in the renal uptake over this interval of time, at least for this group of patients, whose kidneys mainly presented low functional capability.
Thus, in the present study, a simplified method was used to quantify kidneys that were scheduled for nephrectomy. The in vivo ARU was compared with the gold standard, i.e. the "real" quantification of the functional capability of the resected kidney, which was determined as the percentage of the injected radioactivity present in the nephrectomy specimen.
CONCLUSIONS
The method described is simple and precise for estimating the ARU before nephrectomy, without the need for imaging phantoms or complex equations. However, further studies are needed, in order to evaluate the usefulness of this method in kidneys with normal or mildly impaired function.
